MX2023007084A - Inhibidores de pan-kras de azaquinazolina. - Google Patents

Inhibidores de pan-kras de azaquinazolina.

Info

Publication number
MX2023007084A
MX2023007084A MX2023007084A MX2023007084A MX2023007084A MX 2023007084 A MX2023007084 A MX 2023007084A MX 2023007084 A MX2023007084 A MX 2023007084A MX 2023007084 A MX2023007084 A MX 2023007084A MX 2023007084 A MX2023007084 A MX 2023007084A
Authority
MX
Mexico
Prior art keywords
kras
azaquinazoline
pan
kras inhibitors
inhibitors
Prior art date
Application number
MX2023007084A
Other languages
English (en)
Inventor
John David Lawson
Xiaolun Wang
Matthew Arnold Marx
Christopher Ronald Smith
Svitlana Kulyk
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of MX2023007084A publication Critical patent/MX2023007084A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos que inhiben al menos uno de KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D y KRas Q61H, composiciones farmacéuticas que comprenden los compuestos y métodos de uso de estos.
MX2023007084A 2020-12-15 2021-12-15 Inhibidores de pan-kras de azaquinazolina. MX2023007084A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063125776P 2020-12-15 2020-12-15
US202163159868P 2021-03-11 2021-03-11
US202163164338P 2021-03-22 2021-03-22
PCT/US2021/010065 WO2022132200A1 (en) 2020-12-15 2021-12-15 Azaquinazoline pan-kras inhibitors

Publications (1)

Publication Number Publication Date
MX2023007084A true MX2023007084A (es) 2023-08-30

Family

ID=82058749

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007084A MX2023007084A (es) 2020-12-15 2021-12-15 Inhibidores de pan-kras de azaquinazolina.

Country Status (11)

Country Link
US (1) US20230072276A1 (es)
EP (1) EP4262807A1 (es)
JP (1) JP2023553492A (es)
KR (1) KR20230142465A (es)
AU (1) AU2021401232A1 (es)
CA (1) CA3198885A1 (es)
CL (1) CL2023001694A1 (es)
CO (1) CO2023009083A2 (es)
IL (1) IL303446A (es)
MX (1) MX2023007084A (es)
WO (1) WO2022132200A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022061251A1 (en) * 2020-09-18 2022-03-24 Plexxikon Inc. Compounds and methods for kras modulation and indications therefor
KR20240013776A (ko) * 2021-05-28 2024-01-30 레드엑스 파마 피엘씨 Kras 돌연변이 단백질을 억제할 수 있는 피리도[4,3-d]피리미딘 화합물
CA3224105A1 (en) * 2021-06-30 2023-01-05 Huibing Luo Nitrogen-containing heterocyclic compound, and preparation method therefor, intermediate thereof, and application thereof
WO2023020519A1 (en) * 2021-08-18 2023-02-23 Jacobio Pharmaceuticals Co., Ltd. 1, 4-oxazepane derivatives and uses thereof
WO2023020523A1 (en) * 2021-08-18 2023-02-23 Jacobio Pharmaceuticals Co., Ltd. Bicyclic derivatives and use thereof
WO2023020518A1 (en) * 2021-08-18 2023-02-23 Jacobio Pharmaceuticals Co., Ltd. N-cyclopropylpyrido [4, 3-d] pyrimidin-4-amine derivatives and uses thereof
WO2023020521A1 (en) * 2021-08-18 2023-02-23 Jacobio Pharmaceuticals Co., Ltd. Pyridine fused pyrimidine derivatives and use thereof
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023061294A1 (zh) * 2021-10-13 2023-04-20 再鼎医药(上海)有限公司 含氮杂环类衍生物调节剂、其制备方法及应用
CN116253748A (zh) * 2021-12-09 2023-06-13 苏州浦合医药科技有限公司 取代的双环杂芳基化合物作为kras g12d抑制剂
TW202340214A (zh) 2021-12-17 2023-10-16 美商健臻公司 做為shp2抑制劑之吡唑并吡𠯤化合物
TW202340202A (zh) * 2021-12-22 2023-10-16 美國加利福尼亞大學董事會 Gtp酶抑制劑及其用途
WO2023138583A1 (zh) * 2022-01-21 2023-07-27 上海湃隆生物科技有限公司 杂环类化合物、药物组合物及其应用
CN116514848A (zh) * 2022-01-30 2023-08-01 上海璎黎药业有限公司 一种含氮杂环化合物、其制备方法及应用
WO2023154766A1 (en) 2022-02-09 2023-08-17 Quanta Therapeutics, Inc. Kras modulators and uses thereof
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023179703A1 (en) * 2022-03-24 2023-09-28 Beigene , Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith
WO2023213269A1 (en) * 2022-05-06 2023-11-09 Zai Lab (Shanghai) Co., Ltd. Amide-substituted heterocyclic compounds as kras g12d modulators and uses thereof
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2023244600A1 (en) * 2022-06-15 2023-12-21 Mirati Therapeutics, Inc. Prodrugs of pan-kras inhibitors
WO2023246777A1 (en) * 2022-06-20 2023-12-28 Jacobio Pharmaceuticals Co., Ltd. K-ras mutant protein inhibitors
CN117327103A (zh) * 2022-07-01 2024-01-02 苏州泽璟生物制药股份有限公司 取代嘧啶并环类抑制剂及其制备方法和应用
WO2024008068A1 (en) * 2022-07-04 2024-01-11 Jacobio Pharmaceuticals Co., Ltd. K-ras mutant protein inhibitors
WO2024009191A1 (en) * 2022-07-05 2024-01-11 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
WO2024012519A1 (zh) * 2022-07-13 2024-01-18 北京华森英诺生物科技有限公司 Pan-kras抑制剂
CN117624170A (zh) * 2022-08-24 2024-03-01 泰励生物科技（上海）有限公司 具有抗kras突变肿瘤活性的化合物
WO2024061333A1 (zh) * 2022-09-21 2024-03-28 甘李药业股份有限公司 一种kras突变蛋白抑制剂、及其制备方法和应用
CN117777164A (zh) * 2022-09-27 2024-03-29 上海璎黎药业有限公司 一种含氮多环化合物、其药物组合物及应用
WO2024083168A1 (en) * 2022-10-19 2024-04-25 Genentech, Inc. Oxazepine compounds comprising a 6-aza moiety and uses thereof
WO2024083246A1 (en) * 2022-10-21 2024-04-25 Ascentage Pharma (Suzhou) Co., Ltd. Kras inhibitors
WO2024092420A1 (zh) * 2022-10-31 2024-05-10 上海皓元医药股份有限公司 一种((2R,7aS)-2-氟六氢-1H-吡咯嗪-7a-基)甲醇的制备方法
WO2024102421A2 (en) 2022-11-09 2024-05-16 Revolution Medicines, Inc. Compounds, complexes, and methods for their preparation and of their use
CN118047801A (zh) * 2022-11-17 2024-05-17 广东东阳光药业股份有限公司 一种kras抑制剂化合物、其药物组合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2336603T3 (es) * 2005-07-21 2010-04-14 F. Hoffmann-La Roche Ag Compuestos de pirido(2,3-d)pirimidina-2,4-diamina como inhibidores de ptp1b.
US20100210649A1 (en) * 2006-12-21 2010-08-19 Sloan-Kettering Institute For Cancer Research Pyridazinones and furan-containing compounds
KR20200100632A (ko) * 2017-11-15 2020-08-26 미라티 테라퓨틱스, 인크. Ｋｒａｓ ｇ12ｃ 억제제
CA3121236A1 (en) * 2018-12-10 2020-06-18 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
JP2022517222A (ja) * 2019-01-10 2022-03-07 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
AU2020232616A1 (en) * 2019-03-01 2021-09-09 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
MX2022002465A (es) * 2019-08-29 2022-05-19 Mirati Therapeutics Inc Inhibidores de kras g12d.
WO2022031678A1 (en) * 2020-08-04 2022-02-10 Mirati Therapeutics, Inc. Kras g12d inhibitors

Also Published As

Publication number Publication date
US20230072276A1 (en) 2023-03-09
WO2022132200A1 (en) 2022-06-23
CA3198885A1 (en) 2022-06-23
CO2023009083A2 (es) 2023-11-30
CL2023001694A1 (es) 2024-01-19
KR20230142465A (ko) 2023-10-11
JP2023553492A (ja) 2023-12-21
IL303446A (en) 2023-08-01
EP4262807A1 (en) 2023-10-25
AU2021401232A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
MX2023007084A (es) Inhibidores de pan-kras de azaquinazolina.
WO2023150284A3 (en) Quinazoline pan-kras inhibitors
MX2022013430A (es) Metodos para tratar el crecimiento celular anormal.
IL288200A (en) kras g12c inhibitors and their use
MX2022002465A (es) Inhibidores de kras g12d.
Lankheet et al. Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib
EP3844151A4 (en) KRAS G12C INHIBITORS
EP3790551A4 (en) KRAS G12C INHIBITORS
MA54327A (fr) Inhibiteurs de kras g12c
ZA201807256B (en) Inhibitors of activin receptor-like kinase
Tan et al. Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models
MX2019013858A (es) Inhibidores de kras g12c y metodos para su uso.
MX2018013983A (es) Inhibidores g12c de kras.
RU2017131430A (ru) Способ лечения рака, ассоциированного с мутацией ras
Brufsky Cancer treatment-induced bone loss: pathophysiology and clinical perspectives
Michmerhuizen et al. PARP1 inhibition radiosensitizes models of inflammatory breast cancer to ionizing radiation
RS53265B (en) K-RAS MUTATIONS AND ANTI-EGFR ANTIBODY THERAPY
JP2016506908A5 (es)
Zhang et al. Efficacy and safety profile of antibiotic prophylaxis usage in clean and clean-contaminated plastic and reconstructive surgery: a meta-analysis of randomized controlled trials
Guo et al. Neutrophil–to–lymphocyte ratio and use of antibiotics associated with prognosis in esophageal squamous cell carcinoma patients receiving immune checkpoint inhibitors
NZ581176A (en) Stabilized amorphous forms of imatinib mesylate the formulation is a solid dispersion
WO2018183089A8 (en) Compositions for treating and/or preventing cancer
MX2021002805A (es) Terapias de combinacion.
EP3980046A4 (en) KRAS G12V MUTANT THAT BINDS TO JAK1, INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS
MD3347360T2 (ro) Compuși utili pentru inhibarea ROR-gama-t